Like a Bridge over Troubled Water: Keeping the Myeloma Down En Route to CAR-T

Overview

Journal Blood Cancer J

Date 2024 Apr 12

PMID 38609377

Authors

Joshua Richter

Affiliations

Soon will be listed here.

References

Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O . Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022; 3(Suppl 1):39-45. PMC: 9175845. DOI: 10.1002/jha2.335. View

Akhtar O, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli M . Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2023; 30(3):283.e1-283.e10. DOI: 10.1016/j.jtct.2023.12.010. View

Mikhael J, Fowler J, Shah N . Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access. JCO Oncol Pract. 2022; 18(12):800-807. DOI: 10.1200/OP.22.00315. View

Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J . A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Front Immunol. 2023; 14:1169071. PMC: 10154462. DOI: 10.3389/fimmu.2023.1169071. View

Zafar A, Huang C, Lo M, Arora S, Chung A, Wong S . Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma. Transplant Cell Ther. 2023; 29(8):504.e1-504.e7. DOI: 10.1016/j.jtct.2023.05.016. View

Pinnix C, Gunther J, Dabaja B, Strati P, Fang P, Hawkins M . Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020; 4(13):2871-2883. PMC: 7362355. DOI: 10.1182/bloodadvances.2020001837. View

Hubbeling H, Silverman E, Michaud L, Tomas A, Shouval R, Flynn J . Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023; 29(4):259.e1-259.e10. PMC: 10089652. DOI: 10.1016/j.jtct.2022.12.021. View

Sim A, Jain M, Figura N, Chavez J, Shah B, Khimani F . Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019; 105(5):1012-1021. PMC: 6872916. DOI: 10.1016/j.ijrobp.2019.05.065. View

Ababneh H, Yee A, Raje N, Martin S, Frigault M, Ng A . Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiother Oncol. 2023; 189:109933. DOI: 10.1016/j.radonc.2023.109933. View

10.

Afrough A, Hashmi H, Hansen D, Sidana S, Ahn C, Peres L . Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024; 14(1):63. PMC: 11015040. DOI: 10.1038/s41408-024-00993-0. View